Literature DB >> 31149132

SUSPECTED NON-LRP5 MUTATION ASSOCIATED WITH HIGH BONE MASS UNALTERED BY CONCURRENT SYMPTOMATIC PRIMARY HYPERPARATHYROIDISM OF LONG DURATION.

D Grigorie1,2, A Constantini3, A Sucaliuc1,2.   

Abstract

BACKGROUND: Unexplained high bone mass (HBM) (Bone Mineral Density-BMD Z-score at the lumbar spine or hip of ≥+3.2 SD, or a combined spine and hip Z score ≥4 SD) after routine bone densitometry occurs with a prevalence of approximately 2 out of 1.000 and is currently believed to be a mild form of skeletal dysplasia (1).
RESULTS: We present the case of a patient with unexplained HBM (Z-scores at L3, L1-L4, total hip and radius total were +3, +2.7, +2 and +1.8, respectively) and concurrent symptomatic primay hyperparathyroidism (total serum calcium 11.9 mg/dL, serum Parathyroid Hormone - PTH 189.3 pg/mL) of long duration. There were no significant BMD changes at any skeletal site after the surgical cure of hyperparathyroidism. Testing for LRP (low density lipoprotein receptor-related proteins) 5 gene mutations was negative.
CONCLUSIONS: We presented an unusual case of the association of a HBM with primary hyperparathyroidism with resistance to the catabolic action of PTH. In spite of the negative result of LRP5 testing we do believe that a mutation of a gene involved in the Wnt pathway in bone is responsible.

Entities:  

Keywords:  High bone mass; LRP-5; Primary hyperparathyroidism

Year:  2016        PMID: 31149132      PMCID: PMC6535254          DOI: 10.4183/aeb.2016.461

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  10 in total

1.  Linkage of a gene causing high bone mass to human chromosome 11 (11q12-13)

Authors:  M L Johnson; G Gong; W Kimberling; S M Reckér; D B Kimmel; R B Recker
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

2.  A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.

Authors:  Randall D Little; John P Carulli; Richard G Del Mastro; Josée Dupuis; Mark Osborne; Colleen Folz; Susan P Manning; Pamela M Swain; Shan-Chuan Zhao; Brenda Eustace; Michelle M Lappe; Lia Spitzer; Susan Zweier; Karen Braunschweiger; Youssef Benchekroun; Xintong Hu; Ronald Adair; Linda Chee; Michael G FitzGerald; Craig Tulig; Anthony Caruso; Nia Tzellas; Alicia Bawa; Barbara Franklin; Shannon McGuire; Xavier Nogues; Gordon Gong; Kristina M Allen; Anthony Anisowicz; Arturo J Morales; Peter T Lomedico; Susan M Recker; Paul Van Eerdewegh; Robert R Recker; Mark L Johnson
Journal:  Am J Hum Genet       Date:  2001-12-03       Impact factor: 11.025

3.  Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism.

Authors:  S J Silverberg; F Gartenberg; T P Jacobs; E Shane; E Siris; R B Staron; D J McMahon; J P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  1995-03       Impact factor: 5.958

4.  Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5.

Authors:  Morten Frost; Tom Andersen; Fatma Gossiel; Stinus Hansen; Jens Bollerslev; Wim van Hul; Richard Eastell; Moustapha Kassem; Kim Brixen
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

5.  High bone density due to a mutation in LDL-receptor-related protein 5.

Authors:  Lynn M Boyden; Junhao Mao; Joseph Belsky; Lyle Mitzner; Anita Farhi; Mary A Mitnick; Dianqing Wu; Karl Insogna; Richard P Lifton
Journal:  N Engl J Med       Date:  2002-05-16       Impact factor: 91.245

6.  Unexplained high BMD in DXA-scanned patients is generalized throughout the skeleton and characterized by thicker cortical and trabecular bone.

Authors:  S Lomholt; A K Amstrup; E Moser; N F B Jakobsen; L Mosekilde; P Vestergaard; L Rejnmark
Journal:  Calcif Tissue Int       Date:  2015-01-23       Impact factor: 4.333

7.  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.

Authors:  Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

8.  'Sink or swim': an evaluation of the clinical characteristics of individuals with high bone mass.

Authors:  C L Gregson; S A Steel; K P O'Rourke; K Allan; J Ayuk; A Bhalla; G Clunie; N Crabtree; I Fogelman; A Goodby; C M Langman; S Linton; E Marriott; E McCloskey; K E Moss; T Palferman; S Panthakalam; K E S Poole; M D Stone; J Turton; D Wallis; S Warburton; J Wass; E L Duncan; M A Brown; G Davey-Smith; J H Tobias
Journal:  Osteoporos Int       Date:  2011-04-01       Impact factor: 4.507

9.  Missense Mutations in LRP5 Associated with High Bone Mass Protect the Mouse Skeleton from Disuse- and Ovariectomy-Induced Osteopenia.

Authors:  Paul J Niziolek; Whitney Bullock; Matthew L Warman; Alexander G Robling
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

10.  Mutations in Known Monogenic High Bone Mass Loci Only Explain a Small Proportion of High Bone Mass Cases.

Authors:  Celia L Gregson; Lawrie Wheeler; Sarah A Hardcastle; Louise H Appleton; Kathryn A Addison; Marieke Brugmans; Graeme R Clark; Kate A Ward; Margaret Paggiosi; Mike Stone; Joegi Thomas; Rohan Agarwal; Kenneth E S Poole; Eugene McCloskey; William D Fraser; Eleanor Williams; Alex N Bullock; George Davey Smith; Matthew A Brown; Jon H Tobias; Emma L Duncan
Journal:  J Bone Miner Res       Date:  2015-10-06       Impact factor: 6.741

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.